Aspect
Liquid Biopsy
-
What is Aspect Liquid Biopsy?
Aspect Liquid Biopsy uses the latest technology to analyse a bio-fluid sample to assess the genetic makeup of a tumour. The process for patients is the same as a standard blood test which is non-invasive, pain free, and saves time and money without the need to undergo a hospital procedure.
Unlike traditional biopsies which can be invasive, painful and require recovery time, Aspect Liquid Biopsy is non-invasive and drawn from a simple blood test which can detect the recurrence of cancer using DNA biomarkers in melanoma, lung and colorectal cancer patients.
“Aspect Liquid Biopsy allows your Oncologist to monitor and catch the signs of cancer relapse from a simple blood test, aiding the most effective treatment and avoiding invasive procedures.” Associate Professor Mirette Saad, National Clinical Director of Molecular Genetic Pathology, Australian Clinical Labs
View this short video to see how Aspect Liquid Biopsy works:
At Clinical Labs, we currently offer Aspect liquid Biopsy testing for lung cancer, colorectal cancer and melanoma.
-
What are the benefits of liquid biopsy?
- Earlier detection of relapses for colorectal and lung cancer patients
- Non-invasive
- Pain-free
- Reliable, timely results
- No need to undergo a hospital procedure
-
Why is liquid biopsy so important?
Early detection can support better treatment decisions. Aspect Liquid Biopsy can replace the traditional solid tissue biopsy and while traditional biopsies are still required in some cases, Aspect Liquid Biopsy can be effective in the early detection of the recurrence of cancers including melanoma, colorectal and lung.
Aspect Liquid Biopsy can improve patient outcomes and increase survival rates by detecting cancer recurrence earlier than the current conventional methods such as imaging, invasive techniques and blood tumour markers.
To discover more about Aspect Liquid Biopsy, contact your oncologist.
About the Author
Associate Professor Mirette Saad
MBBS(Hons) MD(Hons) MAACB FRCPA PhDAssociate Professor Mirette Saad
MBBS(Hons) MD(Hons) MAACB FRCPA PhD- antenatal screening
- cancer genetics
- clinical research and medical teaching
- endocrine
- fertility testing
- molecular genetics
- nipt
- precision medicine
Associate Professor Mirette Saad is a Consultant Chemical Pathologist and the National Director of Molecular Genetics at Australian Clinical Labs. She has a Fellowship with honours in Chemical and Molecular Pathology, with Microbiology sub-speciality, from overseas. A/P Saad received her NHMRC sponsored PhD degree in Cancer Genetics from Melbourne University and Peter MacCallum Cancer Institute. Along with her teaching and research roles, A/P Saad is a registered medical practitioner with AHPRA, a Chemical Pathology Fellow (FRCPA) at the Royal College of Pathologists of Australasia and a Member of the Australasian Association of Clinical Biochemists (MAACB). She is a Chair of the RCPA Chemical Pathology Advisory Committee, Member of the RCPA Genetic Advisory Committee, AACB and a Chair of the Precision Medicine Services at Australian Clinical Labs. At Clinical Labs, A/Prof Mirette Saad leads the Molecular Genetic testing for NIPT, antenatal screening, personalised drug therapy and cancer.
Related Pages
Pharmacogenetics
Pharmacogenetics (PGx) is the study of how your genes affect the way you respond to medications.
Melaseq
Melaseq uses genomic technology to define the genetic fingerprint of invasive melanoma, aiding doctors to diagnose melanoma more accurately in its early stages.
EndoPredict
EndoPredict is a prognostic test for women with early-stage, ER+, HER2− primary breast cancer.